- Home
- DXC vs MANE Comparison
DXC vs MANE Comparison
Compare DXC & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | MANE |
|---|---|---|
| Founded | 1959 | 2019 |
| Country | United States | United States |
| Employees | 130000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXC | MANE |
|---|---|---|
| Price | $13.33 | $73.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $15.14 | ★ $78.33 |
| AVG Volume (30 Days) | ★ 2.6M | 449.2K |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 356.52 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $12,871,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.23 | $36.26 |
| 52 Week High | $17.26 | $80.90 |
Technical Indicators
Market Signals| Indicator | DXC | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 60.48 | 61.11 |
| Support Level | $12.72 | $54.23 |
| Resistance Level | $14.80 | N/A |
| Average True Range (ATR) | 0.59 | 6.13 |
| MACD | 0.13 | 0.69 |
| Stochastic Oscillator | 90.81 | 72.08 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.